Repeated Dosing with Oral Allosteric Modulator of Adenosine A1 Receptor Produces Tolerance in Rats with Neuropathic Pain

Anesthesiology

Volumn 100, Issue 4, 2004, Pages 956-961

  Li, Xinhui ^a,c   Bantel, Carsten ^a   Conklin, Dawn ^a   Childers, Steven R ^a   Eisenach, James C ^b  

^a Department of Anesthesiology ^*

^b FM James   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (4 CHLOROBENZOYL) 5,6,7,8 TETRAHYDROBENZOTHIOPHENE; ADENOSINE; ADENOSINE A1 RECEPTOR; BENZOTHIOPHENE DERIVATIVE; RADIOLIGAND; T 62; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; LIGAND BINDING; MEMBRANE BINDING; MOBILIZATION; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SEDATION; SPINAL CORD;

ADENOSINE; ADMINISTRATION, ORAL; ALLOSTERIC REGULATION; ANIMALS; DRUG TOLERANCE; MALE; PAIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; SPINAL NERVES; THIOPHENES; XANTHINES;

EID: 1642307808     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200404000-00028     Document Type: Article

References (32)

1. McQuay HJ: Pharmacological treatment of neuralgic and neuropathic pain. Cancer Surv 1988; 7:141-59
2. Kingery WS: A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997; 73:123-39
3. Sawynok J: Adenosine receptor activation and nociception. Eur J Pharmacol 1998; 347:1-11
4. Belfrage M, Segerdahl M, Arner S, Sollevi A: The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain. Anesth Analg 1999; 89:136-42
5. Biaggioni I, Onrot J, Hollister AS, Robertson D: Cardiovascular effects of adenosine infusion in man and their modulation by dipyridamole. Life Sci 1986; 39:2229-36
6. Karlsten R, Gordh TJr, Hartvig P, Post C: Effects of intrathecal injection of the adenosine receptor agonists R-phenylisopropyl-adenosine and N-ethylcarboxamide-adenosine on nociception and motor function in the rat. Anesth Analg 1990; 71:60-4
7. Lee YW, Yaksh TL: Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J Pharmacol Exp Ther 1996; 277:1642-8
8. Sylven C, Beermann B, Jonzon B, Brandt R: Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. BMJ (Clin Res Ed) 1986; 293:227-30
9. Keil GJ, DeLander GE: Spinally-mediated antinociception is induced in mice by an adenosine kinase-, but not by an adenosine deaminase-, inhibitor. Life Sci 1992; 51:L171-6
10. Golembiowska K, White TD, Sawynok J: Adenosine kinase inhibitors augment release of adenosine from spinal cord slices. Eur J Pharmacol 1996; 307:157-62
11. Lavand'homme PM, Eisenach JC: Exogenous and endogenous adenosine enhance the spinal antiallodynic effects of morphine in a rat model of neuropathic pain. Pain 1999; 80:31-6
12. Mizumura T, Auchampach JA, Linden J, Bruns RF, Gross GJ: PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ Res 1996; 79:415-23
13. Kourounakis A, Visser C, de Groote M, IJzerman AP: Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl-]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochem Pharmacol 2001; 61:137-44
14. Bruns RF, Fergus JH: Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990; 38:939-49
15. Pan HL, Xu Z, Leung E, Eisenach JC: Allosteric adenosine modulation to reduce allodynia. ANESTHESIOLOGY 2001; 95:416-20
16. Li X, Conklin D, Ma W, Zhu X, Eisenach JC: Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. Pain 2002; 97:117-25
17. Kim SH, Chung JM: Sympathectomy alleviates mechanical allodynia in an experimental animal model for neuropathy in the rat. Neurosci Lett 1991; 134:131-4
18. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63
19. Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 7:1032-6
20. Chiari A, Yaksh TL, Myers RR, Provencher J, Moore L, Lee CS, Eisenach JC: Preclinical toxicity screening of intrathecal adenosine in rats and dogs. ANESTHESIOLOGY 1999; 91:824-32
21. Shapira Y, Lam AM, Eng CC, Laohaprasit V, Michel M: Therapeutic time window and dose response of the beneficial effects of ketamine in experimental head injury. Stroke 1994; 25:1637-43
22. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 1976; 72:248-54
23. Kowaluk EA, Kohlhaas KL, Bannon A, Gunther K, Lynch JJ III, Jarvis MF: Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice. Pharmacol Biochem Behav 1999; 63:83-91
24. Jarvis MF, Yu H, McGaraughty S, Wismer CT, Mikusa J, Zhu C, Chu K, Kohlhaas K, Cowart M, Lee CH, Stewart AO, Cox BF, Polakowski J, Kowaluk EA: Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. Pain 2002; 96:107-18
25. Gyllenhammar E, Nordfors LO: Systemic adenosine infusions alleviated neuropathic pain. Pain 2001; 94:121-2
26. von Heijne M, Hao JX, Yu W, Sollevi A, Xu XJ, Wiesenfeld-Hallin Z: Reduced anti-allodynic effect of the adenosine A1-receptor agonist R-phenylisopropyladenosine on repeated intrathecal administration and lack of cross-tolerance with morphine in a rat model of central pain. Anesth Analg 1998; 87:1367-71
27. Ahlijanian MK, Takemori AE: Cross-tolerance studies between caffeine and (-)-N6-(phenylisopropyl)-adenosine (PIA) in mice. Life Sci 1986; 38:577-88
28. Ahlijanian MK, Takemori AE: Effects of (-)-N6-(R-phenylisopropyl)-adenosine (PIA) and caffeine on nociception and morphine-induced analgesia, tolerance and dependence in mice. Eur J Pharmacol 1985; 112:171-9
29. Casati C, Monopoli A, Dionisotti S, Zocchi C, Bonizzoni E, Ongini E: Repeated administration of selective adenosine A1 and A2 receptor agonists in the spontaneously hypertensive rat: Tolerance develops to A1-mediated hemodynamic effects. J Pharmacol Exp Ther 1994; 268:1506-11
30. Sharma SK, Nirenberg M, Klee WA: Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci U S A 1975; 72:590-4
31. Buisson B, Bertrand D: Chronic exposure to nicotine upregulates the human (alpha)4(beta)2 nicotinic acetylcholine receptor function. J Neurosci 2001; 21:1819-29
32. Bhattacharya S, Linden J: Effects of long-term treatment with the allosteric enhancer, PD81, 723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors. Mol Pharmacol 1996; 50:104-11